Comparison between venous infliximab blood level and bloodspot-technology in children with inflammatory bowel disease.

Completed

• Conditions: chronic inflammation of the bowel; Inflammatory bowel disease; 10017969

• Registration Number: NL-OMON45579
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

- Patients with Crohn's disease, Ulcerative Colitis and IBD-unclassified
- Age from six to sixteen years old
- Treatment with infliximab
- Indication to determine infliximablevel and anti-drug-antibodies
- Obtain informed consent

Exclusion Criteria

- Age under six and above seventeen years old
- No informed consent
- Children and parents/guardians who do not speak the Dutch language

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study objective is comparison between the venous infliximab blood<br /><br>level/anti-drug-antibodies and the bloodspot-technology. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not apply</p><br>